首页 › 基金 › Samsara BioCapital, LLC › AQST
Samsara BioCapital, LLC 对 AQST 的持仓历史
AQUESTIVE THERAPEUTICS INC · 医疗保健
Samsara BioCapital, LLC 在 Q3 2026 的 13F 申报中披露持有 AQST(AQUESTIVE THERAPEUTICS INC)2,434,367 股,市值约 US$11.3M,约占其申报组合的 1.07%,在其申报持仓中市值排名第 14 位。 Samsara BioCapital, LLC 最近 5 个申报季度中有 5 个季度披露了 AQST 持仓,最早可追溯至 Q3 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Samsara BioCapital, LLC 对 AQST 的持仓演变
Samsara BioCapital, LLC 于 Q3 2025 首次披露 AQST 持仓:2,500,000 股(约 US$14.0M)。 该持仓在 Q4 2025 达到峰值 2,500,000 股,市值约 US$16.1M。 在 5 次申报中,Samsara BioCapital, LLC 0 次增持、1 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 2,434,367 股、市值约 US$11.3M,环比减持 -65,633 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2025 | 2.50M | $13.97M | 新进 |
| Q4 2025 | 2.50M | $16.15M | 持有 |
| Q1 2026 | 2.50M | $10.38M | 持有 |
| Q2 2026 | 2.50M | $10.40M | 持有 |
| Q3 2026 | 2.43M | $11.27M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AQST 与 13F 数据
AQST(AQUESTIVE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 39 只申报持有 AQST,申报仓位最大的包括:Bratton Capital Management, L.P. (US$45.4M), Rosalind Advisors, Inc. (US$9.3M), Propel Bio Management, LLC (US$8.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AQST 的基金
- Bratton Capital Management, L.P. 9.81M 股 · $45.42M · Q3 2026
- Rosalind Advisors, Inc. 2.00M 股 · $9.26M · Q3 2026
- Propel Bio Management, LLC 278.72K 股 · $8.61M · Q3 2026
- Blue Owl Capital Holdings LP 1.39M 股 · $6.44M · Q3 2026
- Sio Capital Management, LLC 1.28M 股 · $5.92M · Q3 2026
- DAFNA Capital Management LLC 640.91K 股 · $2.97M · Q3 2026
- Everstar Asset Management, LLC 614.11K 股 · $2.84M · Q3 2026
- Bracebridge Capital, LLC 459.22K 股 · $2.13M · Q3 2026
更多关于 Samsara BioCapital, LLC
常见问题
How long has Samsara BioCapital, LLC held AQST?
Samsara BioCapital, LLC has disclosed AQST holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Samsara BioCapital, LLC's current position in AQST?
As of Q3 2026, Samsara BioCapital, LLC holds 2.43M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $11.27M, representing 1.07% of its reported portfolio and ranking #14.
Has Samsara BioCapital, LLC been buying or selling AQST?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC reduced its position in AQST. The position peaked in Q4 2025 at 2.50M shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Rosalind Advisors, Inc., Propel Bio Management, LLC, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.